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Summary
Histopathological reports of multiple sclerosis and its
animal models have shown evidence of a link between
axonal injury in active lesions and impaired glutamate
metabolism. Mature oligodendrocytes play a role in glut-
amate uptake to maintain glutamate homeostasis but in
multiple sclerosis white matter the loss of expression of
glutamate transporters in the lesion vicinity results in
ineffective glutamate removal. Using a magnetic reson-
ance spectroscopy technique that isolates the glutamate
resonance at 3 T, we compared glutamate levels between
normal subjects and multiple sclerosis patients in differ-
ent brain areas. Metabolite concentrations (glutamate,
glutamine, N-acetyl-aspartate, myo-inositol, choline, cre-
atine) were derived from LCmodel and corrected for T1
relaxation time. Glutamate concentrations were found
to be elevated in acute lesions (P = 0.02) and normal-
appearing white matter (P = 0.03), with no signiﬁcant
elevation in chronic lesions (P = 0.77). The N-acetyl-
aspartate level in chronic lesions was signiﬁcantly lower
(P < 0.001) than in acute lesions and normal-appearing
white matter. The choline level in acute lesions was
signiﬁcantly higher (P < 0.001) than in chronic lesions.
Evidence was also found for increased glial activity in
multiple sclerosis, with signiﬁcantly higher (P < 0.001)
myo-inositol levels in acute lesions compared with control
white matter. These in vivo results support the hypothesis
that altered glutamate metabolism is present in brains of
multiple sclerosis patients.
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Introduction
Glutamate and glutamine are two important neurochemicals
in the central nervous system. Glutamate is metabolized in the
neurons and released in the synaptic space, where it binds
to its postsynaptic receptors. To clear it from the synaptic
space and prevent neurotoxicity due to continued signalling,
glutamate is internalized into astrocytes (Shousboe et al.,
1993; Rothstein et al., 1994) and converted into glutamine
(Berl and Clarke, 1983). Glutamine then leaves the astrocytes
and is taken up by neurons, where glutaminase regenerates
glutamate, which completes the normal functioning of the
well-known glutamate/glutamine (Shousboe et al., 1993)
cycle. Under pathological conditions an excess of glutamate
in the synaptic space can trigger a toxic cascade leading to
cell death (Lipton and Rosenberg, 1994; Rothstein, 1996).
This neuroexcitotoxicity cascade might have a key role link-
ing the presence of inﬂammation to axonal injury in multiple
sclerosis. Recent histopathological studies (Piani et al., 1991)
of brain tissues have linked, for the ﬁrst time, white matter
axonal injury to the presence of inﬂammatory glutamate-
producing immune cells in proximity to active multiple
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 sclerosis lesions. Moreover, in multiple sclerosis white matter
tissue outside of active plaques, the expression of glutamate
receptors (EAAT-1 and EAAT-2) on the surface of oligoden-
drocytes (glial cell) and the glutamate reuptake are defective
(Pitt et al., 2003). Supporting these results in multiple
sclerosis, the blockade of glutamate receptors was shown
to ameliorate oligodendrocyte survival and neurological
sequelae, and to reduce dephosphorylation of axonal neuro-
ﬁlament in experimental allergic encephalomyelitis (EAE)
(Pitt et al., 2000; Smith et al., 2000). Based on these import-
ant ﬁndings, distant Wallerian degeneration and/or retrograde
degeneration of neurons and neuronal processes derived
from multiple sclerosis lesions (Simon et al., 2000) can
possibly be related, at least in part, by glutamate excitotoxic
events. Excess glutamate in active lesions could therefore
be an important predictor of axonal injury, brain atrophy
and long-term accumulation of clinical disability. Neurotoxic
properties of excess glutamate have been associated with a
wide range of other degenerative diseases, such as amyo-
trophic lateral sclerosis, Huntington disease and Alzheimer
disease (Doble, 1999; Auger and Attwell, 2000). A non-
invasive method of monitoring changes in levels of glutamate
will have a signiﬁcant impact in understanding the patho-
genesis of multiple sclerosis and other neurological diseases.
TE-averaged MRS
Even at 3 T, in conventional short echo spectra, the N-acetyl
group of N-acetyl aspartate (NAA) (2.02 p.p.m.) overlaps
with the C3 protons of glutamate. The C4 protons of glut-
amate at 2.35 p.p.m. are contaminated by C3 protons of NAA,
as well as C3 and C4 protons of glutamine. The co-resonant
signals from the C2 protons of glutamate and glutamine at
3.78 p.p.m. are partly obscured by myo-inositol. The over-
lapping peaks make it difﬁcult to investigate the individual
levels of glutamate and glutamine. Therefore, studies (Hattori
et al., 2002) have focused on the evaluation of the total
glutamate+glutamine levels under pathological conditions.
Several prior studies (Lee et al., 1995; Pan et al., 1996;
Thompson and Allen, 1998) have used the simpliﬁcation
of strong coupling patterns at high ﬁeld strengths to devise
spectral editing methods to resolve the glutamate resonance.
Using a 4.1 T magnet, Pan and colleagues reported that glut-
amate had higher concentrations (2–4 mM higher) in grey
matter compared with white matter (Pan et al., 1996). With
most commercial manufacturers now offering magnets at 3 T,
patient studies are becoming increasingly common at this
ﬁeld strength. It is therefore valuable to have a technique
for measuring glutamate that overcomes the problem of over-
lapping spectral resonance associated with conventional
point-resolved spectroscopy (PRESS) acquisitions at 3 T.
Recent studies have shown differences in glutamate levels
at 3 T between the angular cingulate cortex and hippocampus
usingasingle-echoPRESSsequenceatechotime(TE)=80ms
(Schubert et al., 2004). This single echo acquisition scheme
results in a mixed-phase glutamate detection. Mixed phased
resonances are susceptible to cancellation due to ﬁeld
inhomogeneities and single-echo sequences are sensitive to
biological and pathological variations in T2.
Recently a method was developed by our group (Hurd
et al., 2004) which provides an unobstructed single-line res-
onance detection for glutamate at 2.35 p.p.m. at 3 T that is
distinct from glutamine and NAA. In this method the con-
ventional PRESS localization technique was modiﬁed to
collect data over multiple echo times at ﬁxed increments.
The optimum echo times and increments were determined
using simulations and phantom acquisitions. Using this
scheme it was shown that the zeroth component of this
multi-echo data set, obtained by averaging the different TE
acquisitions, results in a spectrum that isolates the glutamate
resonance. Hereafter, this acquisition scheme will be referred
to as TE-averaged PRESS.
In this study we used the single-voxel TE-averaged PRESS
technique to estimate the levels of glutamate and glutamine
in addition to NAA, choline, creatine and myo-inositol in
contrast-enhancing acute lesions, chronic lesions and
normal-appearing white matter (NAWM) brain areas of mul-
tiple sclerosis patients. These were compared with metabolite
levels in normal control white matter. Metabolite concentra-
tions are estimated using LCmodel (Provencher, 1993) and
corrected for relaxation effects.
Methods
Data acquisition
Data were acquired on a 3 T Signa scanner (Menlo Park, CA, USA)
using the standard quadrature head coil and PROBE/SVQ
TM (auto-
mated PRESS). This sequence was modiﬁed (Hurd et al., 2004) to
collect data in 64 increments of 2.5 ms starting at TE = 35 ms with
a number of averages (NEX) of 4. TR was set at 2s for all studies.
The scan time for this acquisition was 9 min. In multiple sclerosis
patients spectra were derived from an 8cc single voxel in a left or
right parietal NAWM region, surrounding an acute gadolinium
(Gad) enhancing lesion or non-enhancing chronic hypointense T1
lesion. These results were compared with data from a single voxel in
the mostly white matter region in controls. A limited data set was
obtained from the occipital grey matter in controls to determine
glutamate levels in the grey matter.
Data processing
After each examination, the images and raw spectra data were
transferred to a Sun workstation (Sun Microsystems, CA, USA).
Time domain data were extracted from the single-voxel raw ﬁles
using General Electric’s spectroscopy processing tool Sage
TM. The
different echo time water-suppressed acquisitions were averaged
to generate a single TE-averaged free induction decay (FID). This
TE-averaged FID was presented for LCmodel processing without
any spectral apodization or zero-ﬁlling.
Spectral quantiﬁcation
The metabolite concentrations were obtained using LCmodel quan-
tiﬁcation algorithm. LCmodel analyses the in vivo spectrum as a
linear combination of individual in vitro metabolite spectra that
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 constitute a basis set. Hence, LCmodel requires an in vitro basis set
of individual metabolite spectra acquired with similar conditions as
in vivo spectra. In general, the basis set is acquired once for each
acquisition protocol. The basis set used in this study consisted of
spectra from the following metabolites: NAA, choline, creatine,
glutamate, glutamine and myo-inositol. To allow for differences
in machine characteristics between the acquisition of the basis set
and the in vivo spectra, LCmodel uses a calibration factor to scale the
in vitro basis set to the in vivo spectra. The calibration factor was
obtained by using LCmodel to estimate the known concentration of
NAA in the MRS sphere using the same basis set as that used for
in vivo quantiﬁcation. The same calibration factor was then used for
all data sets. The spectral analysis window was conﬁned to 3.85–
1.8 p.p.m. for 3 T data to prevent variability in the results from lipid
artefacts. Spectra were included in the ﬁnal analysis based on quality
criteria deﬁned by objective output parameters from the LCmodel
analysis: sufﬁcient spectral resolution (full width at half minimum
<0.07 p.p.m.), sufﬁcient information (signal-to-noise ratio >4) and
residuals that were randomly scattered about zero to indicate a
reasonable ﬁt.
Error estimates in LCmodel
Errors in metabolite quantiﬁcation in LCmodel are expressed in
percent standard deviation (%SD) of the estimated concentrations
and represent the 95% conﬁdence intervals of the estimated con-
centration values. A percentage standard deviation >50% indicates
that the metabolite concentration could range from zero to twice the
estimated concentration. Hence metabolite concentrations estimated
with percentage standard deviation greater than 50% were taken
to be unreliable and the associated metabolites were assumed to
be undetectable. In this study, quantiﬁcation estimates for NAA,
choline, creatine, glutamate and myo-inositol were included only if
their percentage standard deviation was within 20% and glutamine
concentrations were used only if its percentage standard deviation
was constrained to within 30%.
Correction for MR relaxation times
To estimate T1 relaxation the following acquisition scheme was
used: TE-averaged PRESS acquisition was used to collect data in
16 increments of 5.0 ms starting at 35 ms at repetition time (TR) 2 s
with the number of excitations (NEX) = 8 and then repeated with a
TR of 8 s with NEX = 2. From the longitudinal MR relaxation
equation, if the TR is 5 times the anticipated T1 then a complete
recovery of longitudinal magnetization is expected at TR = 8 s. If the
anticipated T1 is 2 s, then at a TR of 2 s there is 60% recovery of
signal. Hence the chosen TRs provide a robust estimate of T1. The
T1 relaxation times were obtained from a two-point ﬁt to the meta-
bolite spectra at TR = 2 s and TR = 8 s after the respective data sets
had been normalized for the number of excitations.
Within LCmodel the estimated concentration of each metabolite
was corrected for T1 relaxation effects using the correction factor
fTR = (1 – exp[–TR/T1vitro])/(1 – exp[–TR/T1vivo]). Here ‘vitro’
refers to the relaxation values of the metabolites in solution and
were obtained from the work of Ethofer and colleagues (Ethofer
et al., 2003).In this study, the invitro glutamate relaxation value was
0.92 s and the glutamine T1 relaxation values were taken to be the
same as that of glutamate. A relaxation correction factor fTR was
derived for each metabolite based on its relaxation value. Since the
TE-averaged acquisition collects data at different echo times, the
measurement of T2 relaxation times was readily obtained for each
data set simultaneously with the metabolite information. The peak
heights of the respective metabolite peaks at the different echo times
were ﬁtted to a single exponential ﬁt using SAGE
TM (GE Medical
Systems, Milwaukee, WI) T2 ﬁtting to determine the T2 relaxation
times of NAA, choline and creatine.
Correction for oedema
Acute lesions are expected to contain signiﬁcant levels of oedema.
The importance of correcting the volume of interest for oedema was
shown by Helms et al. (2001). In that study, increases in glutamate+
glutamine in acute lesions were apparent only after volumes were
corrected for oedema. In the TE-averaged scheme the largest echo
time data are collected at 185 ms, which is not sufﬁcient to meas-
ure the T2 of water adequately. To estimate the T2 of oedematous
water within an acute enhancing lesion a separate acquisition was
used in which data were collected at eight different echo times,
with the largest echo time at 1.5 s with a scan time of 1 min.
A biexponential ﬁt was used to ﬁt this in vivo decay curve to extract
the short and long components. It has been shown that the relative
size of these components correspond to intra- and extracellular com-
partments (Barnes et al., 1987). The long component, in a region of
interest (VOI) surrounding an acute lesion, was used to estimate the
volume changes due to oedematous extracellular water (Helms
et al., 2001). This volume change was obtained by converting the
long component into the corresponding volume fraction (slong)b y
comparison of 100% water content obtained from a calibration
experiment using a water phantom under similar conditions as the
in vivo experiment. Using the relation Vcorr =( 1–s long) 3 VVOI,
where slong is the volume fraction associated with the long compon-
ent, the corrected volume (Vcorr) can be obtained from the prescribed
VVOI. The LCmodel analysis was then used to estimate metabolite
concentrations using the Vcorr as the VOI for acute enhancing
lesions. The effect of this correction is to increase the metabolite
estimates relative to their uncorrected values.
Statistical comparisons
Statistical comparisons between two samples were made using the
Wilcoxon rank sum test. A P value of 0.05 or less was regarded
as signiﬁcant. The coefﬁcient of variation (CV) was computed
as (RMSE/S (meani)/n)3100, where RMSE = square root
[S(variancei/n)]. Here i represents the ith data set from a total
number of n controls.
Study population
Sixteen controls (eight males and eight females) and 25 multiple
sclerosis patients (13 males and 12 females) were scanned for this
study. The mean age of the controls and patients was 38 6 12 and
42 6 12 years respectively. The patients had a mean disease duration
of 8 6 7 years with a mean EDSS of 3.5 6 2.1 Of the 25 multiple
sclerosis patients, the number and regions of interest investigated
for each patient were as follows: seven patients (NAWM only), ﬁve
patients (NAWM and one chronic voxel), one patient (NAWM +
two chronic), four patients (NAWM + acute lesion), two patients
(two acute lesions each), one patient (acute only), one patient
(chronic + acute) and four patients (chronic only). The diagnosis of
multiple sclerosis was based on the McDonald criteria (McDonald
et al., 2001). Sixteen relapsing–remitting, four secondary progress-
ive and seven primary progressive multiple sclerosis patients from
the University of California San Francisco Multiple Sclerosis
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 Center were asked to participate. All relapsing–remitting patients
and one secondary progressive patient were treated with either inter-
feron b or glatiramer acetate. Primary progressive multiple sclerosis
patients were not treated except for one who was on minocycline
therapy.
All multiple sclerosis patients are followed by clinicians from our
multiple sclerosis Center and are scanned regularly using either rou-
tineclinicalMRIscansoraspartofongoinglongitudinalMRIstudies.
Patients were asked to participate in this MRS study if their last scan
showed an acute contrast-enhancing lesion or a non-enhancing T1-
hypointense lesion present for at least more than 6 months. For
patients with acute contrast-enhancing lesions, all MRS research
scans were performed between 48 h and 2 weeks after the
gadolinium-enhancing lesions had been detected. The University of
CaliforniaatSanFranciscoCommitteeonHumanResearchapproved
the study and all subjects gave their informed written consent.
Results
Differences between conventional and
TE-averaged PRESS
In a conventional 3 T PRESS spectrum at TE 35, glutamate
at 2.35 p.p.m. overlaps with the N-acetyl group of NAA
(2.02 p.p.m.) and glutamine signals, making it difﬁcult to
isolate the glutamate resonance (Fig. 1A). In comparison,
TE-averaged PRESS (Fig. 1B) fully resolves the glutamate
at 2.35 p.p.m. from overlap from NAA and glutamine,
resulting in its unobstructed detection (Hurd et al., 2004).
Figure 2A and B illustrate a TE-averaged spectrum from
an acute enhancing and chronic lesion respectively.
Corrections for MR relaxation time
The relaxation values for the metabolites are shown in
Table 1. As reported in previous studies, the T1 relaxation
values (Table 1A) decrease as NAA > creatine > choline >
myo-inositolandtheT2values(Table1B)asNAA>choline>
creatine. It was observed that the water T1 relaxation values
in NAWM (1.19 6 0.2 s) were longer than those of controls
(0.83 6 0.4 s) but the metabolite T1 relaxation values in
NAWM were shorter than control white matter.
The T2 relaxation values of NAA, choline and creatine
were similar in NAWM relative to control white matter.
Due to the strong J coupling of the glutamate, glutamine
and myo-inositol resonances, their signal does not follow
the single exponential decay behaviour with multiple echo
times, as shown for glutamate in Fig. 3. This ﬁgure was
obtained using GAMMA simulation software (Smith et al.,
1994). This software uses the Bloch equations to determine
how spins behave with the components and timing relation-
ships of the pulse sequence. It was also difﬁcult to ﬁnd a set
of echo times in this curve at which the glutamate signal
was at its maximum phase and not overlapping with other
Fig. 1 Comparison of glutamate detection with conventional PRESS and TE-averaged PRESS at 3 T in an in vivo spectrum. In a
conventional 3 T PRESS spectrum at TE 35 ms (A), glutamate at 2.35 p.p.m. overlaps with the N-acetyl group of NAA (2.02 p.p.m.) and
glutamine signals, making it difﬁcult to isolate the glutamate resonance. In comparison, TE-averaged PRESS (B) fully resolves the
glutamate at 2.35 p.p.m. from overlap from NAA and glutamine, resulting in its unobstructed detection. In this ﬁgure each trace represents
a TE-averaged spectrum of the given metabolite, i.e. NAA, glutamate, glutamine and myo-inositol, obtained from phantoms that only
contained each respective metabolite.
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 metabolites. Hence, the T2 relaxation of glutamate, glutamine
and myo-inositol could not be determined with the TE-
averaged method. Since it was not possible to determine
the T2 relaxation of glutamate, glutamine and myo-
inositol, data were not corrected for T2 relaxation to allow
adequate comparison between all metabolite concentrations.
Reliability of metabolite quantiﬁcation
The reproducibility of the estimated in vivo metabolite
concentrations with LCmodel is illustrated in Table 2.
These values incorporate both methodological and biological
variations. The non-uniform B1 ﬁeld due to the dielectric
effect at 3 T is also a factor contributing to the variability
of LCmodel concentrations. This is expected to affect both
control and multiple sclerosis scans. The reproducibility
of strongly coupled resonances of glutamate and myo-
inositol is similar to singlet resonances, namely NAA
and creatine. It is noted that the resulting differences in
metabolite levels reported in the present study are much
greater than the inherent reproducibility of the technique.
Using the TE-averaged PRESS scheme we found that
the glutamate levels in control white matter was 7m M
compared with 9 mM in grey matter. This is consistent
with prior studies (Pan et al., 1996) which have reported 2
Fig. 2 Representative TE-averaged PRESS spectrum from an 8 ml single voxel (A) surrounding an acute enhancing lesion and
(B) chronic lesion.
Table 1 Metabolite (A) T1 and (B) T2 relaxation times (mean 6 SD) in control white matter and normal-appearing
white matter (NAWM). The T1 values of water in controls and NAWM are also indicated
Water NAA Choline Creatine Myo-inositol Glutamate
(A)
White matter 0.83 6 0.2 1.86 6 0.2 1.32 6 0.2 1.74 6 0.1 1.03 6 0.2 1.23 6 0.2
NAWM 1.19 6 0.4 1.68 6 0.1 1.14 6 0.1 1.59 6 0.2 1.00 6 0.1 1.14 6 0.1
(B)
White matter 0.23 6 0.05 0.18 6 0.03 0.14 6 0.01
NAWM 0.25 6 0.05 0.20 6 0.04 0.14 6 0.02
Elevated glutamate in MS using 3 T MR spectroscopy Page 5 of 10
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 mM higher glutamate levels in grey matter compared with
white matter.
Metabolite levels in multiple sclerosis
Table 3 shows the comparison of metabolite levels of control
white matter, NAWM and regions surrounding acute and
chronic lesions.
Glutamate levels were higher in acute enhancing lesions
(P = 0.02) and NAWM (P = 0.03) relative to control white
matter. No signiﬁcant differences (P = 0.77) were observed
in glutamate levels in chronic lesions relative to control white
matter. The NAA level in chronic lesions was signiﬁcantly
different (P < 0.001) from that in control matter. However,
no signiﬁcant differences were found between NAA levels in
NAWM and acute lesions relative to normal control white
matter. Reliable estimates for glutamine were obtained only
for a subset of the total number of voxels in each case and are
indicated as such in the table. Relative to control white
matter, myo-inositol levels were signiﬁcantly different in
NAWM (P = 0.04), acute lesions (P < 0.001) and chronic
lesions (P = 0.02). Choline levels were signiﬁcantly different
in NAWM (P = 0.03) and acute lesions (P < 0.001) but not in
chronic lesions (P = 0.94). Creatine levels were found to be
somewhat variable across multiple sclerosis regions of inter-
est, with the most difference in acute lesions (P = 0.02)
relative to control white matter.
Oedema correction
Estimates for extracellular water content were 7% in con-
trol white matter and 14% for oedematous acute lesions.
Volume correction for water in a voxel enhances the differ-
ence in glutamate levels between control white matter and
acute lesions from 10% before correction to 19% after
correction (Fig. 4).
Fig. 3 Simulation of the glutamate resonance with multiple
echo times using GAMMA (Smith et al., 1994) software.
Table 2 Estimated concentration (mM) and coefﬁcient of variation (CV) from white matter of normal controls
obtained by TE-averaged PRESS acquisition
NAA Choline Creatine Glutamate Myo-inositol
Concentration (mM) 12.8 6 0.9 2.0 6 0.2 6.9 6 0.4 7.1 6 0.7 3.9 6 0.3
CV (%) 9.3 3.2 8.8 10.3 9.2
The CV was obtained by scanning ﬁve controls at least twice on different days.
Table 3 Concentration of metabolites in control white matter, NAWM and regions surrounding acute and chronic
lesions (mM; mean 6 SD)
NAA Choline Creatine Myo-inositol Glutamate Glutamine
Control white matter 13.4 6 1.7 2.0 6 0.4 7.1 6 1.2 4.3 6 1.2 6.9 6 0.8 5.5 6 2.0
(n = 16) (n = 13)* (n = 7)*
NAWM 12.8 6 2.5 2.4 6 0.4 8.0 6 1.5 5.6 6 1.6 8.1 6 1.6 6.1 6 1.2
(n = 17)
P = 1.0 P = 0.03 P = 0.13 P = 0.04 P = 0.03
(n = 10)*
P = 0.52
(n = 7)*
Contrast-enhancing lesions 12.7 6 1.3 2.6 6 0.3 8.1 6 0.7 6.1 6 0.9 8.0 6 1.0 6.9 6 0.9
(n = 10)
P = 0.44 P = 0.002 P = 0.02 P < 0.001
(n = 8)*
P = 0.02 P = 0.12
(n = 7)*
Chronic lesions 10.8 6 2.0 2.0 6 0.5 7.3 6 1.2 5.9 6 1.8 6.7 6 1.0 5.8 6 1.3
(n = 12)
P < 0.001 P = 0.94 P = 0.56 P = 0.02
(n = 11)*
P = 0.77
(n = 6)*
P = 0.61
(n = 7)*
The highlighted results are signiﬁcantly (P < 0.05) different from controls. Concentrations are reported only if their error estimate with
LCmodel were within 20%for NAA, choline, creatine, glutamate andmyo-inositol (see text) and within 30%for glutamine. Hence, insome
cases metabolite estimates were obtained only for a subset of voxels and are so indicated. Statistics were evaluated using the Wilcoxon
rank-sum test. The distribution of the regions of interest investigated among the different patients is outlined in the text.
*Reliable metabolite estimates were obtained only from a subset of the total voxels indicated.
Page 6 of 10 R. Srinivasan et al.
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Discussion
With a recently developed TE-averaged PRESS MR spectro-
scopic method we were able to unambiguously detect
the glutamate resonance and evaluate its levels in multiple
sclerosis brain in association with other metabolites, NAA,
choline, creatine and myo-inositol. The TE-averaged PRESS
acquisition provides unobstructed detection of glutamate at
3 T at 2.35 p.p.m. and can be considered analogous to the
singlet NAA detection. Besides enhancing the glutamate
estimation in quantiﬁcation schemes, the singlet detection of
glutamate also improves the estimation of glutamine, which
co-resonates with glutamate at 3.75 p.p.m. since the glutam-
ate estimate has been constrained with its estimate at 2.35
p.p.m. Using this method we have also reported levels of
myo-inositol, NAA, choline and creatine.
Corrections for MR relaxation time
Since the concentration estimates are sensitive to metabolite
relaxation values, which can vary between normal and dis-
eased states, we correct for these effects before making com-
parisons of metabolite concentration levels between different
pathologies. All metabolites in this study were corrected for
T1 relaxation, which was obtained from the same region as
the spectra in a separate acquisition. This ensured that the T1
relaxation value adequately represented the same brain region
as spectra. The T1 relaxation value of NAA, choline and
creatine was lower in multiple sclerosis NAWM relative to
white matter in the control. The water T1 relaxation is greater
in the NAWM relative to control white matter, consistent
with our previous studies (Srinivasan et al., 2003) at 1.5 T.
The water T1 relaxation values are higher at 3 T relative to
1.5 T, as expected with increasing ﬁeld strength. This differ-
ence in relaxation time between water and metabolites pos-
sibly follows the results in Ethofer et al. (2003), suggesting
that since metabolites are mainly located inside the cells their
relaxation behaviour depends more on the differences in the
microenvironment, such as cell size, than on tissue integrity
and composition, which determines the T1 relaxation of
water protons. This behaviour of metabolite T1s in multiple
sclerosis NAWM needs further investigation.
The T2 values of NAA, choline and creatine were not
signiﬁcantly different between multiple sclerosis and control
white matter. The difference in T2 values between the present
and our previous study (Hurd et al., 2004) is due to the fact
that in the prior study only echo times greater than 60 ms were
used in the T2 ﬁtting procedure. It was believed that shorter
echo times also contain a component of macromolecular sig-
nal that is not present at the longer echo times due to their
short T2 values. Due to the limitations in the number of echo
times, we were not able to estimate this macromolecular
signal and hence used all the echo times from 35 to 195 ms
to ﬁt the T2 value. These results are consistent with other
studies that have used similar echo times in their ﬁtting pro-
cedure (Mlynarik et al., 2001). While it was not possible to
measure the T2 of glutamate with the TE-averaged technique,
we tried to determine the effect of a T2 relaxation correction
by assuming that the T2 relaxation values for glutamate had
the same relationship and order of magnitude difference
between controls and multiple sclerosis as its T1 relaxa-
tion value. When we incorporated a T2 correction within
LCmodel based on this assumption, we found that the stat-
istical signiﬁcance of the results became even stronger.
Hence, without the T2 relaxation correction the results pre-
sented in this study are conservative estimates.
Metabolite levels in multiple sclerosis
Acute lesions
The inﬂammatory inﬁltrate within active multiple sclerosis
lesions is composed of different populations of activated
T cells, plasma cells, macrophages containing myelin debris
and resident microglia cells, the last two populations being
the most abundant (Traugott et al., 1983; Bruck et al., 1995).
Fig. 4 Glutamate levels without and with volume correction for oedema in Gad enhancing lesions and water content in control
white matter. n = 4 in each case.
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 Themostimportantﬁndingwereportinthisinvivostudyisan
elevation of glutamate in contrast-enhancing areas compared
with white matter areas of normal controls. This is consistent
with active inﬂammatory inﬁltrates, where large quantities of
glutamate are produced and released by activated leucocytes,
macrophages and microglial cells (Piani et al., 1991). It
can be seen as a new in vivo marker of inﬂammation and
its relevance to neuro-axonal injury in multiple sclerosis
will require further investigation. Such elevation was suspec-
ted by Helms and colleagues (Helms et al., 2001), but glut-
amate and glutamine could not be studied separately and
unambiguously.
The extracellular water content in acute enhancing lesions
was approximately twice what was found in normal control
white matter, consistent with the presence of oedema in those
lesions. Using a T2 relaxation method, volume correction for
the oedematous content enhances the differences in glutamate
levels and we recommend using it in the future when studying
metabolites in acute lesions.
Our NAA results (Table 3) in contrast-enhancing areas
are consistent with recent single-voxel studies of contrast-
enhancing lesions using LCmodel (Mader et al., 2000), where
NAA levels did not differ signiﬁcantly from control white
matter areas. We also found an increase in creatine consistent
with high-energy metabolism from hypercellularity (Burtis
and Ashwood, 1994). Taken together, these results certainly
have an implication in multiple sclerosis when interpreting
NAA/creatine ratios as a marker of neuronal loss or dysfunc-
tion within contrast-enhancing areas. Choline was signiﬁc-
antly elevated, possibly due to an increase in cell turnover
and/or myelin debris, as reported previously (Narayana et al.,
1998; Mader et al., 2000; Helms, 2001).
Chronic lesions
Inactive or ‘chronic’ multiple sclerosis plaques are charac-
terized by hypocellularity, absence of myelin breakdown,
prominent ﬁbrillary gliosis and reduced axonal density
(Lassmann, 1998). In our study, glutamate levels were not
different in non-enhancing chronic T1-hypointense areas
compared with control white matter areas. We believe this
is due to the absence or quasi-absence of activated immune
cells in chronic plaques. However, NAA was signiﬁcantly
reduced in chronic T1-hypointense areas with marked eleva-
tion of myo-inositol. Both of these ﬁndings are consistent
with pathological evidence of reduced axonal density and
gliosis. Since NAA is consistently reduced in chronic lesions
(van Walderveen et al., 1999) it would be important to ﬁnd
predictors of this decrease in the early enhancing phase of
lesions. We suspect that glutamate is such a candidate and
certainly deserves careful longitudinal investigation.
Normal-appearing white matter
Several histopathological studies have identiﬁed abnormalit-
ies in NAWM in multiple sclerosis, such as an increase in the
activity or number of glial cells (Allen et al., 2001), changes
in myelin layer organization and membrane proteins (Chia
et al., 1984; Wood and Moscarello, 1984; Newcombe et al.,
1986), reduced axonal density (Evangelou et al., 2000) and
the presence of perivascular T cells, B cells and macrophages
(Prineas and Wright, 1978). Aside from creatine, metabolite
ﬁndings in NAWM in our study followed closely those found
in contrast-enhancing areas. In particular, the excess of
glutamate found in NAWM should mainly relate to the pres-
ence of inﬂammatory cells and astrocytosis. One has to
assume that the glutamate MRS signal detected is mainly
derived from the intracellular compartment, approximately
between 5 and 10 mmol/l, with very little or no contribution
from the extracellular compartment, which under normal con-
ditions is around 0.5–1.0 mmol/l (Leighton et al., 2001) and
below current sensitivity of in vivo MRS. Interestingly, how-
ever, recent studies on human white matter found that key
enzymes of glutamate metabolism and glutamate transporters
were present predominantly on oligodendrocytes and to a
much lesser extent on astrocytes, implying a major role for
oligodendrocytes in the maintenance of glutamate homeo-
stasis in white matter (Pitt et al., 2003). In multiple sclerosis
white matter, oligodendrocytes lost expression of receptors in
the lesion vicinity, resulting in reduced glutamate uptake by
>75% (Pitt et al., 2003) and in ineffective glutamate removal.
This pathological process can only contribute to the detection
of increased glutamate levels in NAWM areas. Glutamate in
NAWM areas will be further investigated to test its relation-
ship with brain atrophy and clinical disability.
NAA in NAWM was not statistically different from control
white matter in this present study, which contrasts with pre-
vious results (Fu et al., 1998; Sarchielli et al., 1999). This
discrepancy could possibly be due to the location of the single
voxel, the volume of NAWM studied, the sample size and
the use of relaxation corrections in quantiﬁcation. We believe
NAA in NAWM should be investigated further from larger
volumes of brain tissue using multivoxel spectroscopic
imaging and T1 corrections.
Our data also suggest a measurable increase in glial activ-
ity, with statistically signiﬁcant differences in myo-inositol
levels in NAWM relative to control white matter areas.
These ﬁndings are consistent with other recent MRS ﬁndings
(Fernando et al., 2004) that have shown increases in myo-
inositol levels in NAWM brain areas of patients presenting
with a clinically isolated syndrome. Myo-inositol levels were
found to correlate with functional impairment measures
using the MSFC scale in clinically deﬁnite RRMS (Chard
et al., 2002) and disability in primary progressive multiple
sclerosis patients (Sastre-Garriga et al., 2003), in whom brain
myo-inositol is synthesized primarily in glial cells and does
not cross the blood–brain barrier (Brand et al., 1993).
Conclusions
Using single voxel TE-averaged PRESS we have acquired
and quantiﬁed in vivo brain metabolites from healthy controls
and multiple sclerosis patients. This technique is optimized
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 for glutamate detection and measurement. This is the ﬁrst
time glutamate, glutamine and myo-inositol have been invest-
igated along with NAA, choline and creatine in the same
cohort of multiple sclerosis patients. Glutamate was found to
be elevated in acute contrast-enhancing lesions and NAWM.
We will investigate whether increase in glutamate relates to
neurotoxicity by predicting axonal injury and brain atrophy
using cross-sectional and longitudinal studies.
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